



Corrigendum: High Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer

Nándor Polk², Barna Budai^{3*}, Erika Hitre⁴, Attila Patócs^{1,3,5*} and Tamás Mersich²

¹Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary, ²Department of Visceral Surgery, National Institute of Oncology, Budapest, Hungary, ³Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary, ⁴Medical Oncology and Clinical Pharmacology “B” Department, National Institute of Oncology, Budapest, Hungary, ⁵Clinical Central Laboratory, National Institute of Oncology, Budapest, Hungary

Keywords: neutrophil-to-lymphocyte ratio, liver-only metastases of rectal cancer, metastasectomy, relapse-free survival, systemic immune-inflammation index, liver-only metastases of colon cancer, preoperative treatment

OPEN ACCESS

Edited by:

Andrea Ladányi,
National Institute of Oncology (NIO),
Hungary

*Correspondence:

Barna Budai
budai.barna@oncol.hu
Attila Patócs
patocs.attila@med.semmelweis-
univ.hu

Received: 17 June 2022

Accepted: 20 July 2022

Published: 06 October 2022

Citation:

Polk N, Budai B, Hitre E, Patócs A and Mersich T (2022) Corrigendum: High Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer. *Pathol. Oncol. Res.* 28:1610658. doi: 10.3389/pore.2022.1610658

A Corrigendum on

High Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer

by Polk N, Budai B, Hitre E, Patócs A and Mersich T (2022). *Pathol. Oncol. Res.* 28:1610315. doi: 10.3389/pore.2022.1610315

In the published article, there was an error in the order of the affiliations. The original list read:

Nándor Polk¹, Barna Budai^{2*}, Erika Hitre³, Attila Patócs^{2,4,5} and Tamás Mersich¹

¹Department of Visceral Surgery, National Institute of Oncology, Budapest, Hungary

²Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary

³Medical Oncology and Clinical Pharmacology “B” Department, National Institute of Oncology, Budapest, Hungary

⁴Clinical Central Laboratory, National Institute of Oncology, Budapest, Hungary

⁵Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary

The corrected list is:

Nándor Polk², Barna Budai^{3*}, Erika Hitre⁴, Attila Patócs^{1,3,5,*} and Tamás Mersich²

¹Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary

²Department of Visceral Surgery, National Institute of Oncology, Budapest, Hungary

³Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary

⁴Medical Oncology and Clinical Pharmacology “B” Department, National Institute of Oncology, Budapest, Hungary

⁵Clinical Central Laboratory, National Institute of Oncology, Budapest, Hungary

A new corresponding author has been included. The correct correspondence footnote is:

*Correspondence: Barna Budai, budai.barna@oncol.hu; Attila Patócs, patocs.attila@med.semmelweis-univ.hu

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2022 Polk, Budai, Hitre, Patócs and Mersich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.